Personalized facial rehabilitation program for systemic sclerosis
Part of Skin clinical trials.
This trial tests a personalized rehabilitation program aimed at improving facial symptoms in people with systemic sclerosis. It may help you with facial involvement while researchers measure how well the program works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have systemic sclerosis diagnosed using the 2013 ACR/EULAR criteria
- Have facial involvement with a MHISS score greater than 6
- Have been on the same immune-suppressing and/or anti-fibrosis treatment for at least 1 month
- Be able to understand the study and sign informed consent
- Be covered by the health insurance system used for the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.